

POSTER PRESENTATION

Open Access

Short-chain sphingolipids for enhanced cellular uptake of liposome-encapsulated amphiphilic anti-cancer drugs

Lília RC Pedrosa^{1*}, Albert van Hell², Wim van Blitterswijk², Ann LB Seynhaeve¹, Alexander MM Eggermont¹, Timo LM ten Hagen¹, Marcel Verheij^{2,3}, Gerben A Koning¹

From 16th International Charles Heidelberger Symposium on Cancer Research
Coimbra, Portugal. 26–28 September 2010

Short-chain sphingolipids, such as C₈-Glucosylceramide (C₈-GC) have been described to enhance the cellular uptake of amphiphilic drugs, in free form or when co-formulated in liposomes (1,2). The involved mechanism is currently unknown, but is hypothesized to induce domain or pore formation in the plasma membrane (3). The aim of this study is to further explore this specific drug uptake process by C₈-GC to enhance intracellular delivery of liposomal doxorubicin.

Liposomes, containing different percentages of incorporated C₈-GC were prepared and loaded with doxorubicin. Characterization was performed by measuring size, polydispersity index (pdi), phospholipid and doxorubicin content. In vitro anti-tumor activity was studied towards a panel of human tumor cell lines and normal cells: endothelial cells and fibroblasts.

Doxorubicin liposomes (Dox-L) enriched with 10 mol% C₈-GC presented less fluctuation in size and pdi than 15 mol% and efficiently retained their contents under culture conditions (10% serum). In all tumor cell lines tested C₈-GC-Dox-L exerted increased cytotoxicity, resulting in up to 20 fold lower IC₅₀ values compared to standard Dox-L. This effect was not observed with endothelial cells and with fibroblasts it was much less pronounced.

In conclusion, 10 mol% C₈-GC-enriched Dox-L had optimal stability and showed enhanced cytotoxicity towards tumor cells and not towards normal cells. Based on these findings, modification of Dox-L

formulations with 10 mol% of C₈-GC can be used to improve drug delivery to tumor cells.

Author details

¹Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus MC- Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. ²Division of Cellular Biochemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ³Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Published: 24 September 2010

References

1. Veldman RJ, Zerp S, van Blitterswijk WJ, Verheij M: N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. *Br J Cancer* 2004, **90**:917-925.
2. Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, van Blitterswijk WJ: Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. *J Pharmacol Exp Ther* 2005, **315**:704-710.
3. Siskind LJ: Mitochondrial ceramide and the induction of apoptosis. *J Bioenerg Biomembr* 2005, **37**:143-153.

doi:10.1038/sj.bjc.6601581

Cite this article as: Pedrosa et al.: Short-chain sphingolipids for enhanced cellular uptake of liposome-encapsulated amphiphilic anti-cancer drugs. *BMC Proceedings* 2010 **4**(Suppl 2):P39.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

 **BioMed Central**

* Correspondence: l.cordeiropedrosa@erasmusmc.nl

¹Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus MC- Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Full list of author information is available at the end of the article